Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
BRIDGEWATER, N.J., March 08, 2017 -- Clinical Genomics, a private company developing evidence-based diagnostic tools for colorectal cancer, today announced it has signed agreements to participate in Fortified Provider Network and MultiPlan’s preferred provider organization (PPO) plans.
Under the new agreements, Colvera™ will be available to patients in both networks. Together, these networks cover approximately 70 million individuals.
Launched in 2016, Colvera is a clinically validated blood test designed to detect colorectal cancer (CRC) recurrence. Colvera detects circulating tumor DNA, small fragments of genetic material that leak from a tumor into the blood stream, by testing for methylation in two genes that have been associated with CRC, BCAT1 & IKZF1.
“Through the agreements with Fortified Provider Network and MultiPlan, many patients who have previously undergone treatment for colorectal cancer will have access to Colvera for recurrence monitoring,” said Lawrence LaPointe, Ph.D., President and CEO of Clinical Genomics. “Having these established partners in place is critical as we continue to focus on expanding the availability of Colvera nationally. We look forward to productive relationships with both provider groups.”
About Colorectal Cancer
Colorectal cancer (CRC) is one of the leading causes of cancer-related deaths worldwide, accounting for more than 600,000 deaths each year. When diagnosed early, before cancer has spread, the relative five-year survival rate for CRC is 90 percent, but approximately four out of 10 CRC cases are detected early. Among individuals undergoing surgical treatment for CRC, recurrence occurs in 30 to 50 percent of all cases, the majority of which present in the first two to three years following initial diagnosis and treatment.
About Clinical Genomics
Clinical Genomics is a privately held biotechnology company developing and marketing innovative products for colorectal cancer (CRC) diagnosis. With a broad intellectual property portfolio consisting of more than 95 patents, Clinical Genomics offers colorectal cancer screening and monitoring solutions. In 2016, Clinical Genomics launched Colvera™, a sensitive and specific blood-based circulating tumor DNA (ctDNA) test for colorectal cancer recurrence monitoring that detects methylated DNA from two genes, BCAT1 and IKZF1. Via its wholly-owned subsidiary Enterix Inc., the company offers the user-friendly, patient-preferred colorectal cancer screening InSure® FIT™ assay, an FDA-cleared fecal immunochemical test that detects blood in the stool.
Clinical Genomics has offices and CLIA-registered laboratories in Bridgewater as well as FDA-registered and TGA-licensed IVD manufacturing in Edison, New Jersey and Sydney, Australia and a NATA-accredited laboratory in North Ryde, NSW Australia.
For more information, please visit www.colveratest.com and www.clinicalgenomics.com.
About Fortified Provider Network
FPN was founded in 1997 in Scottsdale, Arizona for the purpose of creating an all direct-contracted network of preferred providers for our group health clients. Given our superior results in the group health arena, FPN expanded over the years to offer workers’ compensation and auto liability networks. FPN offers the utilization of its network to its payer clients and members who, in turn, are able to capitalize on the discounted fee schedules FPN has negotiated with its healthcare providers.
Currently, FPN contracts with physicians, hospitals, ancillary facilities, mid-level providers and other specialty healthcare providers who have the option of participating in one or more of our products (group health, workers compensation or auto liability). To learn more, visit www.fortifiedprovider.com.
About MultiPlan
MultiPlan, Inc. is the industry’s most comprehensive provider of healthcare cost management solutions. The company provides a single gateway to a host of network- and analytics-based solutions for managing the financial risks associated with healthcare claims as well as products that fight waste, abuse and fraud before payments are made. Clients include insurers, health plans, third party administrators, self-funded employers, HMOs and other entities that pay medical bills in the commercial healthcare, government, workers compensation and auto medical markets. MultiPlan is owned by Hellman & Friedman.
Media Contact: Danielle Lewis, Lazar Partners (212) 843-0211 or (917) 907-4239 [email protected]
